Concourse Financial Group Securities, Inc. Neurocrine Biosciences Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

A detailed history of Concourse Financial Group Securities, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 661 shares of NBIX stock, worth $81,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares

661

Previous 669 1.2%

Holding current value

$81,950

Previous $92,000 17.39%

% of portfolio

0.0%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$114.58 - $153.15 $916 - $1,225	-8 Reduced 1.2%	661 $76,000
Q2 2024 Jul 23, 2024	BUY	$130.86 - $143.19 $9,291 - $10,166	71 Added 11.87%	669 $92,000
Q1 2024 Apr 30, 2024	BUY	$130.4 - $143.74 $6,128 - $6,755	47 Added 8.53%	598 $82,000
Q4 2023 Feb 07, 2024	BUY	$106.07 - $132.76 $10,925 - $13,674	103 Added 22.99%	551 $72,000
Q3 2023 Oct 25, 2023	BUY	$94.02 - $117.1 $14,103 - $17,565	150 Added 50.34%	448 $50,000
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $24,173 - $28,314	-270 Reduced 47.54%	298 $28,000
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $752 - $984	-8 Reduced 1.39%	568 $57,000
Q4 2022 Jan 30, 2023	SELL	$106.72 - $127.06 $32,763 - $39,007	-307 Reduced 34.77%	576 $0
Q3 2022 Nov 15, 2022	SELL	$92.03 - $107.81 $36,812 - $43,124	-400 Reduced 31.18%	883 $94,000
Q2 2022 Aug 09, 2022	SELL	$75.79 - $100.07 $6,593 - $8,706	-87 Reduced 6.35%	1,283 $125,000
Q1 2022 May 09, 2022	SELL	$72.45 - $94.81 $14,779 - $19,341	-204 Reduced 12.96%	1,370 $128,000
Q4 2021 Feb 07, 2022	BUY	$79.65 - $106.22 $13,779 - $18,376	173 Added 12.35%	1,574 $134,000
Q3 2021 Nov 09, 2021	BUY	$86.18 - $99.03 $39,211 - $45,058	455 Added 48.1%	1,401 $134,000
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $894 - $1,022	10 Added 1.07%	946 $92,000
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $13,135 - $17,910	150 Added 19.08%	936 $91,000
Q4 2020 Feb 02, 2021	BUY	$86.91 - $108.33 $10,516 - $13,107	121 Added 18.2%	786 $75,000
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $36,252 - $50,951	377 Added 130.9%	665 $64,000
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $5,956 - $9,125	70 Added 32.11%	288 $35,000
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $4,506 - $6,825	-60 Reduced 21.58%	218 $19,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $8,853 - $12,094	102 Added 57.95%	278 $30,000
Q3 2019 Nov 13, 2019	BUY	$83.82 - $101.5 $2,011 - $2,436	24 Added 15.79%	176 $16,000
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $3,900 - $4,928	-54 Reduced 26.21%	152 $13,000
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $4,990 - $6,590	72 Added 53.73%	206 $18,000
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $3,552 - $6,466	52 Added 63.41%	134 $9,000
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $8,108 - $10,319	82 New	82 $10,000

Others Institutions Holding NBIX

# of Institutions

621

Shares Held

95.7M

Call Options Held

583K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account

Concourse Financial Group Securities, Inc. Neurocrine Biosciences Inc Transaction History